Axsome Therapeutics is a clinical-stage biopharmaceutical company that develops therapies for the management of central nervous system (CNS) disorders. The Company works on product candidates for the treatment of resistant depression and Alzheimer's disease agitation, complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes. It is also developing a preclinical product candidate for CNS disorders, including chronic pain.

Type
Public
HQ
New York, US
Founded
2012
Size (employees)
23 (est)+5%
Website
axsome.com
Axsome Therapeutics was founded in 2012 and is headquartered in New York, US
Report incorrect company information

Key People/Management at Axsome Therapeutics

Herriot Tabuteau

Herriot Tabuteau

Chief Executive Officer
John Golubieski

John Golubieski

CFO
Robert Niecestro

Robert Niecestro

VP, Head of Regulatory Affairs

Axsome Therapeutics Office Locations

Axsome Therapeutics has an office in New York
New York, US (HQ)
25 Broadway, 9th Floor
Show all (1)
Report incorrect company information

Axsome Therapeutics Financials and Metrics

Axsome Therapeutics Financials

USD

Net income (Q2, 2017)

(7.1 m)

EBIT (Q2, 2017)

(6.8 m)

Market capitalization (25-Apr-2018)

60.4 m

Cash (30-Jun-2017)

38 m
Axsome Therapeutics's current market capitalization is $60.4 m.
Annual
USDFY, 2016

General and administrative expense

6.3 m

R&D expense

21.2 m

Operating expense total

27.5 m

EBIT

(27.5 m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

General and administrative expense

1.4 m1.5 m1.6 m1.7 m1.7 m

R&D expense

4.5 m5.3 m5.6 m6 m5 m

Operating expense total

5.9 m6.8 m7.2 m7.7 m6.8 m

EBIT

(5.9 m)(6.8 m)(7.2 m)(7.7 m)(6.8 m)
Annual
USDFY, 2016

Cash

36.6 m

Inventories

2.6 m

Current Assets

38 m

Total Assets

38.2 m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

44.1 m38.8 m33.9 m45 m38 m

Current Assets

45.1 m39.9 m34.8 m46.2 m38.8 m

Total Assets

45.1 m40 m34.9 m46.4 m39 m

Accounts Payable

1.8 m3 m3.9 m4.7 m4 m
Annual
USDFY, 2016

Net Income

(27.2 m)

Depreciation and Amortization

20.5 k

Inventories

(383.9 k)

Accounts Payable

2.2 m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(5.9 m)(12.7 m)(19.9 m)(8 m)(15.1 m)

Depreciation and Amortization

2.1 k5.1 k10.7 k10.1 k20.5 k

Accounts Payable

(61.9 k)1.1 m2 m659.5 k(42.5 k)

Cash From Operating Activities

(3.9 m)(9.3 m)(14.1 m)(6.6 m)(13.7 m)
USDY, 2017

Financial Leverage

1.7 x
Show all financial metrics
Report incorrect company information